These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33037768)

  • 1. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    De Munck TJI; Xu P; Verwijs HJA; Masclee AAM; Jonkers D; Verbeek J; Koek GH
    Liver Int; 2020 Dec; 40(12):2906-2916. PubMed ID: 33037768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colonic permeability is increased in non-cirrhotic patients with nonalcoholic fatty liver disease.
    De Munck TJI; Verhaegh P; Spooren C; Mujagic Z; Wienhold T; Jonkers D; Masclee AAM; Koek GH; Verbeek J
    Dig Liver Dis; 2023 May; 55(5):614-621. PubMed ID: 36710170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Soppert J; Brandt EF; Heussen NM; Barzakova E; Blank LM; Kuepfer L; Hornef MW; Trebicka J; Jankowski J; Berres ML; Noels H
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2746-2758. PubMed ID: 36470528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
    World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.
    Ferolla SM; Couto CA; Costa-Silva L; Armiliato GN; Pereira CA; Martins FS; Ferrari Mde L; Vilela EG; Torres HO; Cunha AS; Ferrari TC
    Nutrients; 2016 Jun; 8(7):. PubMed ID: 27367724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
    Song Q; Zhang X
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
    Kessoku T; Kobayashi T; Tanaka K; Yamamoto A; Takahashi K; Iwaki M; Ozaki A; Kasai Y; Nogami A; Honda Y; Ogawa Y; Kato S; Imajo K; Higurashi T; Hosono K; Yoneda M; Usuda H; Wada K; Saito S; Nakajima A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
    Ismaiel A; Leucuta DC; Popa SL; Dumitrascu DL
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal permeability in non-alcoholic fatty liver disease: the gut-liver axis.
    Scarpellini E; Lupo M; Iegri C; Gasbarrini A; De Santis A; Tack J
    Rev Recent Clin Trials; 2014; 9(3):141-7. PubMed ID: 25514911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
    Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
    APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
    Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
    World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction.
    Krawczyk M; Maciejewska D; Ryterska K; Czerwińka-Rogowska M; Jamioł-Milc D; Skonieczna-Żydecka K; Milkiewicz P; Raszeja-Wyszomirska J; Stachowska E
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.